ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020
Prevalence of Scabies and Impetigo 3 Years After Mass Drug Administration With Ivermectin and Azithromycin.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Prevalence and determinants of scabies: A global systematic review and meta-analysis.Tropical medicine & international health : TM & IH · 2024Pooled it
- Mass Drug Administration for the Control of Scabies: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Pooled it
- One versus two doses of ivermectin-based mass drug administration for the control of scabies: A cluster randomised non-inferiority trial.PLoS neglected tropical diseases · 2023Trial
- Community control strategies for scabies: A cluster randomised noninferiority trial.PLoS medicine · 2021Trial
- A Case-Control Study of Risk Factors for Scabies Among Patients Attending Dermatology Clinics in Afghanistan.Health science reports · 2026Article
- Tracing the Itch: A Spatiotemporal Analysis of Scabies Rates and Its Risk Factors Using the Global Burden of Disease 2021 Data.Tropical medicine & international health : TM & IH · 2025Article
- Prevalence and risk factors of scabies among orphans: A cross-sectional study in Bangladesh.PLoS neglected tropical diseases · 2025Article
- Ivermectin therapy for young children with scabies infection: a multicentre phase 2 non-randomized trial.The Lancet regional health. Western Pacific · 2024Article
- Secondary Bacterial Infections in Patients with Atopic Dermatitis or Other Common Dermatoses.American journal of clinical dermatology · 2024Review
- Prevalence and risk factors of scabies among children living in Madrasahs (Islamic religious boarding schools) of Bangladesh: a cross-sectional study.BMJ paediatrics open · 2024Article
- Prevalence and determinants of impetigo in Ghana: a cross-sectional study.BMC infectious diseases · 2024Article
- Prevalence of scabies and its associated environmental risk factors among the Forcibly Displaced Myanmar Nationals living in the Cox's Bazar district of Bangladesh.Journal of migration and health · 2024Article
- Modelling mass drug administration strategies for reducing scabies burden in Monrovia, Liberia.Epidemiology and infection · 2023Article
- Scabies prevalence after ivermectin-based mass drug administration for lymphatic filariasis, Samoa 2018-2019.PLoS neglected tropical diseases · 2023Article
- Beliefs, attitudes and practices towards scabies in central Ghana.PLoS neglected tropical diseases · 2023Article
- Prevalence of scabies and associated factors among children aged 5-14 years in Meta Robi District, Ethiopia.PloS one · 2023Article
- Mass drug administration of antibacterials: weighing the evidence regarding benefits and risks.Infectious diseases of poverty · 2022Review
- Prevention of bacterial complications of scabies using mass drug administration: A population-based, before-after trial in Fiji, 2018-2020.The Lancet regional health. Western Pacific · 2022Article
- Can ivermectin mass drug administrations to control scabies also reduce skin and soft tissue infections? Hospitalizations and primary care presentations lower after a large-scale trial in Fiji.The Lancet regional health. Western Pacific · 2022Article
- Health care cost of crusted scabies in Aboriginal communities in the Northern Territory, Australia.PLoS neglected tropical diseases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundIvermectin-based mass drug administration has emerged as a promising strategy for the control of scabies and impetigo in settings where the diseases are endemic. Current follow-up data are limited to 12 months for the majority of studies. Longer-term data are vital to inform the sustainability of interventions.
methodsWe conducted a prevalence survey for scabies and impetigo in 10 villages in Choiseul Province of the Solomon Islands 36 months after a single round of ivermectin and azithromycin mass drug coadministration. In the primary analysis, we compared the prevalence of scabies and impetigo at 36 months to the prevalence at baseline.
resultsAt 36 months, the prevalence of scabies was 4.7% (95% confidence interval [CI], 3.6-6.1), which was significantly lower than at baseline (18.7%; relative reduction, 74.9%; 95% CI, 61.5%-87.7%; P < .001). The prevalence of impetigo was 9.6% (95% CI, 8.1%-11.4%), significantly lower than at baseline (24.7%; relative reduction, 61.3%; 95% CI, 38.7%-100%; P < .001). The highest prevalence of scabies was among children aged <5 years (12.5%; adjusted odds ratio, 33.2; 95% CI, 6.6-603.2), and the highest prevalence of impetigo was among children aged 5-9 years (16.4%; adjusted odds ratio, 8.1; 95% CI, 3.6-21.8).
conclusionsThere was a sustained impact of a single round of ivermectin and azithromycin mass drug coadministration on the prevalence of scabies and impetigo 3 years after the intervention. Our data provide further support to adopt this intervention as a central component of global scabies control efforts. CLINICAL TRIALS REGISTRATION: Australian and New Zealand Trials Registry (ACTRN12615001199505).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.